A small-molecule inhibitor of SHIP1 reverses age- and diet-associated obesity and metabolic syndrome

Neetu Srivastava, … , John D. Chisholm, William G. Kerr


Low-grade chronic inflammation is a key etiological phenomenon responsible for the initiation and perpetuation of obesity and diabetes. Novel therapeutic approaches that can specifically target inflammatory pathways are needed to avert this looming epidemic of metabolic disorders. Genetic and chemical inhibition of SH2-containing inositol 5’ phosphatase 1 (SHIP1) has been associated with systemic expansion of immunoregulatory cells that promote a lean-body state; however, SHIP1 function in immunometabolism has never been assessed. This led us to investigate the role of SHIP1 in metabolic disorders during excess caloric intake in mice. Using a small-molecule inhibitor of SHIP1 (SHIPi), here we show that SHIPi treatment in mice significantly reduces body weight and fat content, improves control of blood glucose and insulin sensitivity, and increases energy expenditure, despite continued consumption of a high-fat diet. Additionally, SHIPi reduces age-associated fat in mice. We found that SHIPi treatment reverses diet-associated obesity by attenuating inflammation in the visceral adipose tissue (VAT). SHIPi treatment increases IL-4–producing eosinophils in VAT and consequently increases both alternatively activated macrophages and myeloid-derived suppressor cells. In addition, SHIPi decreases the number of IFN-γ–producing T cells and NK cells in VAT. Thus, SHIPi represents an approach that permits control of obesity and diet-induced metabolic syndrome without apparent toxicity.

Find the latest version:

http://jci.me/88544-pdf
A small-molecule inhibitor of SHIP1 reverses age- and diet-associated obesity and metabolic syndrome

Neetu Srivastava,1 Sonia Iyer,1 Raki Sudan,1 Christie Youngs,1 Robert W. Engelman,2 Kyle T. Howard,3 Christopher M. Russo,1 John D. Chisholm,3 and William G. Kerr1,3,4

1Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, New York, USA. 2Departments of Pathology and Cell Biology and Pediatrics, H. Lee Moffitt Comprehensive Cancer Center and Research Institute, University of South Florida, Florida, USA. 3Department of Chemistry, Syracuse University, Syracuse, New York, USA. 4Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York, USA.

Low-grade chronic inflammation is a key etiological phenomenon responsible for the initiation and perpetuation of obesity and diabetes. Novel therapeutic approaches that can specifically target inflammatory pathways are needed to avert this looming epidemic of metabolic disorders. Genetic and chemical inhibition of SH2-containing inositol 5′ phosphatase 1 (SHIP1) has been associated with systemic expansion of immunoregulatory cells that promote a lean-body state; however, SHIP1 function in immunometabolism has never been assessed. This led us to investigate the role of SHIP1 in metabolic disorders during excess caloric intake in mice. Using a small-molecule inhibitor of SHIP1 (SHIPi), here we show that SHIP1 treatment in mice significantly reduces body weight and fat content, improves control of blood glucose and insulin sensitivity, and increases energy expenditure, despite continued consumption of a high-fat diet. Additionally, SHIPi reduces age-associated fat in mice. We found that SHIP1 treatment reverses diet-associated obesity by attenuating inflammation in the visceral adipose tissue (VAT). SHIPi treatment increases IL-4–producing eosinophils in VAT and consequently increases both alternatively activated macrophages and myeloid-derived suppressor cells. In addition, SHIPi decreases the number of IFN-γ–producing T cells and NK cells in VAT. Thus, SHIPi represents an approach that permits control of obesity and diet-induced metabolic syndrome without apparent toxicity.

Introduction

Obesity and its associated metabolic disorders has become a global epidemic affecting millions of people worldwide. It is now well recognized that metabolism and immunity are closely integrated, and recent evidence suggests that low-grade chronic inflammation within the visceral adipose tissue (VAT) promotes the onset of obesity and insulin resistance (1). Infiltration of inflammatory macrophages and their subsequent production of the proinflammatory cytokines TNF-α and IL-1β in adipose tissue are primarily responsible for the initiation of inflammatory response in the metabolic tissue. Subsequently chronic inflammation in the VAT is maintained by IFN-γ–producing CD4 and CD8 T cells (2). Immune-regulatory cells, both T lymphoid (Treg) and myeloid (alternatively activated macrophages [AAM] and myeloid suppressor cells), play a pivotal role in opposing these inflammatory stressors in VAT to limit inflammation and maintain the lean state and proper control of blood glucose concentration (2–6). Group 2 innate lymphoid cells (ILC2), via production of the Th2 cytokines IL-5 and IL-13, promote increased numbers of IL-4–producing eosinophils, which, in turn, via IL-4–production promote increased numbers of immunoregulatory AAM in VAT that consequently maintain the lean state and metabolic control (7–10).

Low-grade chronic inflammation is a key etiological phenomenon responsible for the initiation and perpetuation of obesity and diabetes. Novel therapeutic approaches that can specifically target inflammatory pathways are needed to avert this looming epidemic of metabolic disorders. Genetic and chemical inhibition of SH2-containing inositol 5′ phosphatase 1 (SHIP1) has been associated with systemic expansion of immunoregulatory cells that promote a lean-body state; however, SHIP1 function in immunometabolism has never been assessed. This led us to investigate the role of SHIP1 in metabolic disorders during excess caloric intake in mice. Using a small-molecule inhibitor of SHIP1 (SHIPi), here we show that SHIP1 treatment in mice significantly reduces body weight and fat content, improves control of blood glucose and insulin sensitivity, and increases energy expenditure, despite continued consumption of a high-fat diet. Additionally, SHIPi reduces age-associated fat in mice. We found that SHIP1 treatment reverses diet-associated obesity by attenuating inflammation in the visceral adipose tissue (VAT). SHIPi treatment increases IL-4–producing eosinophils in VAT and consequently increases both alternatively activated macrophages and myeloid-derived suppressor cells. In addition, SHIPi decreases the number of IFN-γ–producing T cells and NK cells in VAT. Thus, SHIPi represents an approach that permits control of obesity and diet-induced metabolic syndrome without apparent toxicity.
essential for production of the inflammatory cytokine IFN-γ by NK cells responding to stress ligands recognized by the NCR1/NKp46 activating receptor (17, 18). Stressed cells in adipose tissue promote IFN-γ production by NK cells via the NCR1/NKp46 receptor, and their local production of IFN-γ in VAT has recently been shown to be pivotal in the inflammatory cascade that promotes loss of systemic metabolic control (19). Recently, small-molecule SHIP1 inhibitors have been developed (20, 21) and have been shown to promote in vivo increases of immunoregulatory cells, including Tregs and MDSC/AAM, comparable to those seen in SHIP1 mutant mice (20, 22). We hypothesized then that treatment of mice with a SHIP1 inhibitor (SHIPi) would promote Th2 cytokine production and increase immunoregulatory cell numbers in VAT. This immunoregulatory environment would then antagonize inflammatory cell function in VAT associated with high caloric intake and thereby promote maintenance of lean body mass and normal glucose control.

**Results**

**SHIPi treatment prevents obesity and improves glucose homeostasis.** To investigate the role of SHIP1 in obesity and metabolic disorders, we initially tested our recently developed water-soluble SHIPi, K118, on diet-induced obese (DIO) mice (21). DIO mice (12–16 weeks old) maintained on a high-fat diet (HFD) were treated with K118 or vehicle for 4 weeks (2 times/week; 10 mg/kg), and the kinetics of their weight change over the course of the treatment was examined. DIO mice treated with K118 had significant \( P < 0.0001 \) loss of both body weight (Figure 1A) and fat (Figure 1, B and C) as compared with mice before treatment and vehicle-treated mice. Histological analysis revealed that the cellularity of brown adipose tissue (BAT) from K118-treated mice was increased based on enumeration of nuclei and the presence of smaller, multiple lipid droplets observed in individual BAT adipocytes (Figure 1D). No significant differences in overall adipose cellularity were observed in the inguinal white adipose tissue (iWAT) of vehicle-treated mice and K118-treated mice (Figure 1D).

Because K118 treatment substantially reduces fat accumulation and weight gain in HFD-fed DIO mice, we further investigated whether K118 treatment improves impaired control of blood glucose levels that occurs in DIO mice. K118-treated DIO mice showed significantly reduced blood glucose levels (fasting and ad libitum) in comparison to mice before treatment and vehicle-treated mice following 1 month of K118 treatment (Figure 1, E and F). In addition, K118-treated mice had significantly lower serum insulin levels (Figure 1G). Importantly, we observed improved glucose tolerance in K118-treated mice in comparison to vehicle-treated mice, as demonstrated by their response in the intraperitoneal glucose tolerance test (Figure 1H). Thus, K118 treatment also significantly improves control of blood sugar and improves insulin sensitivity in obese hosts despite their continued consumption of a high caloric diet.

In addition to diet, there are many other factors that induce obesity, and aging is one of them. We thus extended our study to test the therapeutic potential of K118 on aged C57BL/6 mice. Corroborating our findings with the DIO mice, K118 treatment considerably reduced body weight and percentage of body fat (Figure 1, I–L) in both male and female 8- to 12-month-old mice, indicating that, irrespective of gender, K118 is also effective at reducing age-associated body fat accumulation.

A short-term SHIPi treatment is sufficient enough to reduce adiposity, increase energy expenditure, and promote lean physiology in DIO mice. Because long-term treatment of K118 dramatically improved metabolic parameters, we then tested if a short-term SHIPi regimen is sufficient enough to improve energy expenditure and lean physiology in DIO mice. Within 2 weeks of initiation of K118 treatment, we found significant reduction in body weight of DIO mice treated with K118, while vehicle-treated mice continued to increase body mass (Figure 2A). In addition, K118-treated mice had significantly lower adiposity and increased lean mass as compared with vehicle-treated controls (Figure 2, B and C). Young chow-fed lean mice treated with K118 did not show significant difference in weight (Figure 2D). However, there was a reduction in body fat in these mice (Figure 2E), and, as with obese mice, we also observed an increase in lean mass of the K118-treated chow-fed mice (Figure 2F). Notably, the epidydimal white adipose tissue (eWAT) mass was also significantly decreased in the K118-treated mice maintained on a HFD (Figure 2, G and H). We also found that K118 increased UCP1 expression in the iWAT (Figure 2I) and increased cellularity and UCP1 expression in thermogenic BAT (Figure 2J) of mice maintained on a HFD. To further characterize the effect of K118 on metabolism, after 2 weeks of K118 or vehicle treatment, HFD-fed obese mice and chow-fed lean young mice were placed in metabolic cages and energy expenditure was determined. Oxygen consumption (\( V_{O_2} \)), carbon dioxide release (\( V_{CO_2} \)), and energy utilization were significantly enhanced.
Figure 1. K118 treatment prevents obesity and improves glucose homeostasis. Phenotypic and metabolic parameters were assessed in 14- to 16-week-old DIO mice treated with K118 (10 mg/kg body weight) or vehicle for 4 weeks (twice per week). (A) Growth curves were plotted to show the changes in body weight of vehicle- and K118-treated mice (n = 6). Two-way ANOVA tests for repeated measurement were performed; P < 0.0001. (B) Percentage of body fat was measured in vehicle- and K118-treated mice before (Pre-Tx) and after treatment (n = 10). (C) Representative gross appearance and comparison of fat depots of DIO mice after either vehicle or K118 treatment. (D) Representative H&E-stained sections of BAT (scale bar: 300 μm) and WAT (scale bar: 500 μm). (E) Fasting and (F) ad libitum blood glucose levels (mg/dl) in pretreated mice and vehicle- and K118-treated DIO C57BL/6 mice (n = 10). (G) Fasting and ad libitum serum insulin levels (pg/ml) measured in vehicle- and K118-treated DIO mice (n = 10). (H) i.p. glucose tolerance test on vehicle- and K118-treated DIO mice (n = 6). Two-way ANOVA tests for repeated measurement were performed followed by post-hoc Bonferroni test. (I and J) Body weight and percentage of fat were measured in aged C57BL/6 mice treated with K118 (10 mg/kg body weight) or vehicle for 4 weeks (twice per week). Changes in body weight of (I) male and (J) female 8- to 12-month-old vehicle- and K118-treated C57BL/6 mice before and after treatment (n = 10). (K and L) Percentage of body fat was measured in vehicle- and K118-treated (K) male and (L) female aged C57BL/6 mice before and after treatment (n = 10). All results are expressed as mean ± SEM. Student’s unpaired, 2-tailed t test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. WAT, white adipose tissue; BAT, brown adipose tissue; DIO, diet-induced obese. Box-and-whisker plots are defined as follows: the bounds of the boxes indicate SD; the lines within the boxes indicate means, and the whiskers represent minimum and maximum values.
in K118-treated mice as compared with the controls (Figure 2, K–M and Supplemental Figure 1, A–C; supplemental material available online with this article; doi:10.1172/jci.insight.88544DS1). Interestingly, food intake in K118-treated mice was increased (Figure 2N); however, their total physical activity (Figure 2O) was not significantly increased or decreased relative to vehicle controls. These data suggest that the increased caloric expenditure by K118 treatment is not due to appetite suppression or enhanced physical activity; instead, K118 acts physiologically in metabolically relevant tissues to improve oxidative metabolism to promote leanness.

SHIP inhibition increases eosinophils in VAT of HFD-induced obese mice. As type 2 cytokines play a pivotal role in metabolic homeostasis in mice (7, 9), we initially investigated whether SHIPi promotes type 2 cytokine production in the DIO mouse model. Mice administered K118 (SHIPi) exhibited significantly increased circulating levels of IL-5 and IL-13 as compared with vehicle-treated control mice (Figure 3, A and B). ILC2 and eosinophils are major producers of type 2 cytokines within VAT (7, 9, 10, 23). We then examined the frequencies of these cells in VAT. Although the frequencies of IL-5– and IL-13–expressing ILC2 were not significantly changed by SHIPi (Supplemental Figure 2A), the frequency and number of eosinophils were significantly increased in the eWAT of K118-treated mice (Figure 3C and Supplemental Figure 2B). However, we also found increased numbers of IL-4–expressing eosinophils in the eWAT of K118-treated mice (Figure 3D), indicating that K118 not only increases eosinophil numbers in VAT, but also promotes their production of IL-4. Consistent with this hypothesis, K118 decreased SHIP1 expression in eosinophils found in eWAT (Figure 3E), confirming that K118 directly targets SHIP1 in eosinophils present in a target tissue.

SHIP inhibition increases MDSC and promotes polarization of macrophages toward M2 phenotype. Consistent with increased numbers of IL-4–producing eosinophils in the eWAT, treatment with K118 led to a large expansion of CD11b+Gr1+ myeloid cells in VAT (Figure 4A). These cells were confirmed to be MDSC, as they express both Arginase1 and IL4Ra (Figure 4B). K118 treatment also significantly decreased SHIP1 expression in MDSC (Figure 4C), suggesting that, similar to eosinophils, K118 directly targets SHIP1 in MDSC of VAT. MDSC have also been shown to suppress adipose inflammation and to promote insulin sensitivity in a diet-induced mouse model of obesity (24). In addition to this, K118-treated VAT eosinophils and MDSC showed increased activation of AKT based on analysis of its phosphorylation (pAKT) (Supplemental Figure 2, C and D). Both eosinophils and MDSC are associated with promoting polarization of macrophages toward AAM or M2 cells in VAT. AAM or M2 cells have been implicated in the maintenance of a lean state and normal glucose homeostasis (6, 7, 24, 25). We thus examined the status of macrophages in the eWAT of K118-treated mice. Indeed, macrophages were skewed toward M2 macrophages or AAM in K118-treated mice maintained on a HFD, as we found a significant decrease in the M1/M2 ratio in VAT (Figure 4D and Supplemental Figure 2E). Also, AAM/M2 macrophages present in the VAT of K118-treated mice on a HFD showed a significantly increased density of IL4Ra and Arginase1 expression when compared with vehicle-treated controls (Figure 4, E and F). Altogether, these data demonstrate that K118 treatment promotes an immunosuppressive environment in the VAT of obese mice by increasing Th2 cytokine expression, expanding the number of IL-4–producing eosinophils and MDSC, and thereby polarizing macrophage differentiation toward an AAM/M2 phenotype.

SHIP inhibition reduces inflammatory effector functions of T cells and NK cells within VAT. During obesity progression, M1 macrophages initiate the inflammatory process, but chronic inflammation is maintained by
Figure 3. K118 treatment increases eosinophils in the visceral adipose tissue of DIO mice. (A and B) 14- to 16-week-old diet-induced obese (DIO) mice treated with K118 (10 mg/kg body weight) or water (vehicle) for 2 weeks (twice per week), followed by determination of IL-5 and IL-13 cytokines serum levels (pg/ml) by ELISA (n = 13–15). (C) Flow cytometry plots showing gating for eosinophils and frequency (total viable epidydimal white adipose tissue [eWAT]) and number of eosinophils in the eWAT of K118- and vehicle-treated mice (n = 15). (D) Flow cytometry plots showing analysis IL-4–expressing SiglecF⁺ eosinophils, their frequencies (percentage of eosinophils), and numbers in the eWAT (n = 10). (E) Expression of SHIP1 in the eosinophils of eWAT of DIO mice (n = 5) treated for 2 weeks with K118 (red) or vehicle (blue). Student’s t test,*P < 0.05,**P < 0.01. Data are represented as mean ± SEM. Sample sizes are biological replicates. Box-and-whisker plots are defined as follows: the bounds of the boxes indicate SD; the lines within the boxes indicate means, and the whiskers represent minimum and maximum values.
Figure 4. K118 treatment expands myeloid suppressor cells and promotes M2 polarization of visceral adipose tissue macrophages. (A) Flow cytometry plots showing CD11b⁺Gr1⁺ cells (MDSC) in vehicle- and K118-treated mice, with box-and-whisker plots indicating their frequencies and numbers (n = 14–15). (B) Histogram showing expression of Arginase1 and IL4Ra (red) compared to fluorescence minus one (FMO, gray) control stain on CD11b⁺Gr1⁺ cells of K118-treated eWAT. (C) Expression of SHIP1 in the CD11b⁺Gr1⁺ cells of eWAT of DIO mice treated for 2 weeks with K118 (red) or vehicle (blue); FMO control is shown in gray (n = 5). (D) Flow cytometry plot showing M1 and M2 macrophages after first gating for live CD11b⁺F4/80⁺ cells (n = 14–15). (E) Expression of IL4Ra (n = 14–15) and (F) Arginase1 (n = 10) in M2 macrophages of K118-treated (red) and vehicle-treated (blue) eWAT. Student’s t test, *P < 0.05, **P < 0.001, ***P < 0.001, ****P < 0.0001. Data are represented as mean ± SEM. Sample sizes are biological replicates. eWAT, epidydimal white adipose tissue. Box-and-whisker plots are defined as follows: the bounds of the boxes indicate SD; the lines within the boxes indicate means, and the whiskers represent minimum and maximum values.
the adaptive immune system (26, 27); thus, we subsequently compared T cells in the eWAT of K118- and vehicle-treated mice on a HFD. The frequency and number of both CD3+CD4+ and CD3+CD8+ T cells were significantly decreased in the eWAT of K118-treated mice (Figure 5, A and B). In addition, IFN-γ-expressing CD4 and CD8 T cells were also significantly reduced in the eWAT of K118-treated mice (Figure 5, C and D). Previous work has linked Tregs to the maintenance of immunosuppression in WAT and prevention of obesity (3, 28). Despite a reduction in the frequency of total CD4+ T cells in eWAT of K118-treated mice (Figure 5A), the frequency of Tregs, CD4+CD25+FoxP3+ cells (nTreg), and CD4+CD25 FoxP3+ cells (iTreg) was not significantly altered relative to vehicle-treated controls (Figure 5E). Thus, K118 sustains the immunosuppressive Treg compartment during high caloric stress in WAT.

Inflammation caused by IFN-γ produced from NK cells has recently been associated with exacerbating diet-induced obesity (DIO) in mice (19). Given the crucial requirement of SHIP1 in NK cell effector function, (17, 18, 29), we next examined the effect of K118 treatment on NK cell frequency and production of IFN-γ in the VAT of DIO mice. Our analysis revealed that K118 treatment in DIO mice considerably decreased the frequency and number of NK cells in the eWAT (Figure 5F). Frequencies of NK1.1+CD3+ NKT cells were also reduced in the K118-treated mice; however, the absolute numbers remain unchanged (Figure 5G). In addition, IFN-γ–producing NK cells and NKT cells were also considerably reduced in the K118-treated eWAT (Figure 5, H and I). Taken together, our findings demonstrate that K118 treatment attenuates inflammatory cell components triggered by high caloric stress, while simultaneously expanding immunoregulatory cell components within the VAT of mice on a HFD.

**Discussion**

These data demonstrate that SHIP1 inhibition promotes immunocalming in VAT and can do so even under adipose tissue stress associated with consumption of a high caloric diet. SHIPi appears to do this by targeting SHIP1 expression in eosinophils and MDSC to expanded numbers of IL-4–producing eosinophils and MDSC, respectively, and consequently polarization of macrophages to the AAM/M2 type. Interestingly, SHIPi can mediate this effect without directly affecting ILC2 homeostasis and their production of Th2 cytokines. Consistent with the increased immunoregulatory environment promoted by SHIPi in VAT, we saw significant reductions in IFN-γ–producing T cells and NK cells. However, SHIPi could also act directly on NK cells in VAT to mediate the latter effect, as SHIP1 is required in an NK cell autonomous fashion for production of IFN-γ in response to NCR1/NKp46 stimulation (18). Although the effects that we have documented show that K118 can target SHIP1 in vivo in cell types that control inflammation in the VAT, we cannot exclude the possibility that K118 also inhibits the SHIP1 paralog, SHIP2, and that this activity of K118 may also contribute to weight loss in obese mice.

Genetic mutation of SHIP1 is associated with severe inflammation of the lungs (30, 31) and small intestine (32, 33) and osteoporosis (34, 35, 36). However, the pulsatile K118 dosing utilized in the above experiments for a 1-month period in DIO mice did not result in any of these pathologies. K118-treated mice lacked any evidence of inflammation in the lungs or small intestine or other organs, such as the kidney, spleen, and liver (Supplemental Figure 3, A–F). In addition, extended dosing with K118 did not negatively affect bone density and mineral content (Supplemental Figure 3, G and H). Moreover, no significant morbidity or mortality was observed in K118-treated mice. Thus, K118 can prevent or reduce diet-induced as well as age-associated weight gain and obesity without adversely affecting the health and viability of the host. These studies reveal that SHIP1 can be targeted to modulate the immune milieu in VAT and importantly demonstrate that SHIP1 inhibitory compounds like K118 offer a nontoxic, therapeutic intervention for obesity and its associated metabolic disorders.

**Methods**

**Mice.** For studies of aged mice, male and female mice were 8- to 12-month-old C57BL6/J retired breeders purchased from Charles River. DIO C57BL6/J mice were 4- to 5-month-old males purchased from Jackson Labs. DIO C57BL6/J mice were fed a high-fat 60 kcal% diet (Research Diets D12492) ad libitum.

**K118 treatment of mice.** K118 was dissolved in water and was injected at 10 mg/kg. The vehicle groups were injected with pure H2O. Mice were injected i.p. with the drug or vehicle twice a week for 2 weeks for short-term treatment and for 4 weeks for long-term treatment.

**Isolation of immune cells from adipose tissue and flow cytometry.** eWAT was digested in 6 ml of Collagenase II buffer (Collagenase II, 2 mg/ml; Sigma-Aldrich, 0.5 % BSA in 1X PBS) at 37°C with shaking...
at 200 rpm in an orbital shaker for 20 minutes. Digested tissue was filtered through a 100-μm filter and centrifuged at 500 g for 10 minutes. Floating adipocytes were removed, and the pellet containing stromal vascular fraction (SVF) was resuspended in 2 ml of rbc lysis buffer (eBioscience). Cells were washed and Fc blocked for 20 minutes, followed by standard flow cytometry surface staining using fluorochrome-conjugated antibodies for 30 minutes on ice. Cells were washed twice and stained with the live/dead aqua dead stain kit for 30 minutes on ice (Life Technologies). The following combination of antibodies was used for staining: anti-mouse CD11c-PEcy7 (N418), CD3-PEcy7 (145-2C11), CD4-FITC (RM4-5), CD45-PerCPcy5.5 (30-F11) FoxP3-PE (FJK-16s), CD25-APC (PC61.5), NK1.1-PerCPcy5.5 (PK136), F4/80-Alexa fluor488 (BM8), CD19-PerCPcy5.5 (eBio1D3, 1D3), IL7Rα-Alexa fluor 700 (A7R34), ST2-Alexa fluor 488 (RMST2-2) from eBioscience; Siglec F-PE (E50-2440), CD45-APCcy7 (30-F11) Gr1-BV605 (RB6-8C5), CD11b- APC cy7 (M1/70), IL4Rα-BV421 (mIL-1R-M1), CD86-Pe (GL1), CD8-APCH7 (53-6.7), and lineage cocktail- PerCPcy5.5 (catalog 561317) from BD Bioscience; SHIP1-Alexa fluor 488 (catalog 656604) from Biolegend; and Arginase1-APC (catalog IC5868A) from R&D Systems. Stained cells were acquired on a BD LSR Fortessa flow cytometer (BD Biosciences), and data were analyzed using FlowJo software version 9.6.4 (Tree Star Inc.)
Intracellular cytokine analysis. To examine effector cytokine production, single-cell suspension of SVF was stimulated with following concentrations of PMA and Ionomycin (Sigma-Aldrich) in the presence of 1 μg/ml brefeldin A (BD Bioscience) for 4 hours at 37°C in a CO₂ incubator. For IFN-γ production from T cells and NK cells, PMA (10 ng/ml) and Ionomycin (1μg/ml) were used. For IL-5, IL-13 production from ILC2, and IL4 from eosinophils, PMA (40ng/ml) and Ionomycin (500ng/ml) were used. Cells were then washed, surface stained, fixed, and permeabilized using fix perm buffer (eBioscience), followed by intracellular staining with IFN-γ-APC, IL-5-APC, IL-13-PE, and IL4–FITC antibodies from eBioscience.

DEXA analysis. Body composition was measured before and after treatment with a PIXImus2 densitometer (GE) and analyzed with software version 1.46 and 2.10, due to system upgrade. Results from both versions were essentially the same, and all results are reported using version 2.10. Mice were anesthetized with isoflurane throughout body scan.

Blood glucose and glucose tolerance test. Peripheral blood glucose levels were assessed using an Accu-Chek Compact Plus meter. Control solution was used to verify the validity of the meter prior to data collection for each treatment group. Glucose was measured both ad libitum and after the mice had fasted for 8 to 15 hours. Anesthesia was not used during sample collection. To test for impairment of glucose disposal, glucose tolerance tests were performed using the same Accu-Chek meter and control solution protocol as above. Mice were fasted for 15 hours and then monitored for 120 minutes after i.p. injection of 2 g glucose/kg body weight. Anesthesia was not used when collecting samples.

Metabolic analysis. Whole-animal metabolic analysis was performed using Comprehensive Laboratory Animals Monitoring System (CLAMS) cages as per the manufacturer’s instructions (Columbus Instruments). For total body composition, live and unaesthetized mice were measured using a quantitative magnetic resonance instrument, EchoMRI, (Echo Medical Systems, LLC). For energy expenditure, food intake, and activity, mice were placed in a CLAMS cage (Columbus Instruments) for assessment. This 16-chamber indirect calorimeter measured the exchange of oxygen for carbon dioxide. In addition, the center feeders allowed for food intake to be measured. These chambers are configured with dual-axis detection of animal motion for animal activity monitoring. The Mouse Metabolic Phenotyping Center at the University of Cincinnati, Ohio, USA, performed all the metabolic analysis.

Cytokine analysis. Peripheral blood samples were collected into Sarstedt serum tubes. Blood was processed as per the manufacturer’s recommendations, and sera were collected and frozen at −20°C. Serum samples were diluted 1:4 for the insulin assays following protocol guidelines. Samples were processed according to the Bio-Rad Bio-Plex Diabetes Assay Manual and were read on a Bio-Rad Bio-Plex 200 instrument. The SUNY Upstate Microarray Core Facility processed samples.

Histological analysis. Tissues were fixed in 10% neutral buffered formalin and embedded in paraffin. Four-micron-thick sections were stained with H&E or rabbit anti-UCP1 antibody (Abcam, ab10983) for immunohistochemistry. Histological images were captured using an Aperio Scanscope (AT2) Digital Pathology Slide Scanner (Leica Biosystems). The Koch Institute Swanson Biotechnology Center processed the brown and white fat tissue samples after fixation. The Department of Pathology at H. Lee Moffitt Comprehensive Cancer Center and Research Institute, University of South Florida, processed all other tissues.

Statistics. All statistical analyses were performed using Prism 5.0 and 6.0 statistical software (GraphPad) and are presented as mean ± SEM. Statistical significance was determined by using 2-tailed Student’s t test for single variables and 2-way ANOVA followed by Bonferroni post test for multiple variables. P values of less than 0.05 were considered statistically significant.

Study approval. Animal experiments were approved by the Institutional Animal Care and Use Committee of SUNY Upstate Medical University. Metabolic studies performed at the Mouse Metabolic Phenotyping Center at the University of Cincinnati and were approved by IACUC of University of Cincinnati.

Author contributions
NS, SI, and WGK designed the study, analyzed data, and wrote the manuscript. NS, SI, and RS, performed all experiments, analyzed data, and generated all the figures. CY performed weight analysis. KTH, CMR, and JDC synthesized K118. JDC edited the manuscript RWE analyzed H&E-stained sections.
Acknowledgments

This work was supported in part by grants from the NIH (RO1 HL72523, RO1 HL085580, RO1 HL107127) and the Paige Arnold Butterfly Run. WGK is the Murphy Family Professor of Children’s Oncology Research and an Empire Scholar of State University of New York and was a Senior Scholar of the Crohn’s and Colitis Foundation of America during this study. We thank the Koch Institute Swanson Biotechnology Center for technical support. We thank Bingbing Yuan and George W. Bell from the Whitehead Institute for Biomedical Research for assistance with statistical analysis of energy expenditure of DIO mice.

Address correspondence to: William G. Kerr, Departments of Pediatrics and Microbiology and Immunology, SUNY Upstate Medical University, 750 East Adams Street, 2204 Weiskotten Hall, Syracuse, New York 13210, USA. Phone: 315.464.5850; E-mail: kerrw@upstate.edu.


